Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $188,781 - $293,580
-14,356 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$20.24 - $36.01 $290,565 - $516,959
14,356 New
14,356 $297,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.